The FDA warned that GLP-1 receptor agonists carry a potential risk of NAION, a rare but serious eye condition associated with sudden vision loss. The agency required manufacturers to inform patients and clinicians about the risk, underscoring how large-scale real-world use can reveal rare adverse events not always captured in pre-approval trials. The update is likely to intensify pharmacovigilance scrutiny for the blockbuster weight-loss and diabetes drugs as regulators and companies update label language, patient information materials, and monitoring guidance. Clinicians may also need to factor NAION risk discussions into ongoing prescribing decisions, particularly for patients with predisposing optic nerve factors.